Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.
The company reported second-quarter sales of $11.14 billion, beating the consensus of $11.07 billion. The U.S. MedTech giant reported adjusted earnings of $1.26, beating the consensus of $1.25, and within the management guidance of $1.23-$1.27.
